PIMAPotassium Iodide Point-of-Care Testing for CD4 Counts in Predicting Antiretroviral Initiation in HIV-Infected Individuals in KwaZulu-Natal; Durban; South Africa
South. Afr. j. HIV med. (Online)
; 17(1): 1-8, 2016.
Article
em En
| AIM
| ID: biblio-1272210
Biblioteca responsável:
CG1.1
ABSTRACT
Introduction:
Limited information is available on the usefulness of the PIMATM analyser in predicting antiretroviral treatment eligibility and outcome in a primary healthcare clinic setting in disadvantaged communities in KwaZulu-Natal; South Africa.Materials andmethods:
The study was conducted under the eThekwini Health Unit; Durban; KwaZulu-Natal. Comparison of the enumeration of CD4+ T-cells in 268 patients using the PIMATM analyser and the predicate National Health Laboratory Services (NHLS) was undertaken during January to July 2013. Bland-Altman analysis to calculate bias and limits of agreement; precision and levels of clinical misclassification at various CD4+ T-cell count thresholds was performed.Results:
There was high precision of the PIMATM control bead cartridges with low and normal CD4+ T-cell counts using three different PIMATM analysers (%CV 5). Under World Health Organization (WHO) guidelines (
Texto completo:
1
Base de dados:
AIM
Assunto principal:
Iodeto de Potássio
/
Infecções por HIV
/
Antirretrovirais
Tipo de estudo:
Guideline
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article